This content is machine translated Obesity: A Multimodal and Interdisciplinary Approach New Swiss Clinical Practice Guideline Provides Guidance The guidelines developed by Swiss professional associations (Swiss Obesity Clinical Practice Guidance) contain evidence-based recommendations for the diagnosis and treatment of obesity, with a focus on improving health, quality of...…
View Post 6 min This content is machine translated Advanced Thyroid Cancer Molecular Mechanisms and New Therapeutic Approaches Thyroid carcinomas exhibit remarkable biological heterogeneity, which is increasingly shaping modern diagnosis and treatment. Molecular markers and innovative treatment approaches are fundamentally changing our understanding of pathogenesis, prognosis, and clinical...…
View Post 18 min This content is machine translated From Risk Identification to Anti-Inflammatory Intervention Inflammation as a Treatment Goal in Its Own Right For decades, cardiovascular prevention was essentially a story about cholesterol. Yet a significant proportion of patients experience adverse events despite optimally controlled lipid levels—a reflection of a residual risk that...… CME-Test
View Post 11 min This content is machine translated Cardiometabolism Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon Incretin-based obesity therapy has advanced rapidly in just a few years: from GLP-1 receptor agonists (semaglutide) to the dual GIP/GLP-1 agonist tirzepatide and on to a triple agonist. Retatrutide (LY3437943)...…
View Post 4 min This content is machine translated MASH Pharmacotherapies as “Game Changers”—What Are the Upcoming Challenges? Two drug therapy options—semaglutide (s.c.) and resmetirom (oral)—are now approved in the EU and the U.S. for the treatment of MASH. This is a major breakthrough, especially since, for a...…
View Post 13 min This content is machine translated Obesity Treatment Oral GLP-1 Therapies: ATTAIN-1 and OASIS-4—The Next Leap Forward Injectable GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide have redefined pharmacological obesity treatment and achieved weight loss in the range of 15 to 20% in clinical trials. Nevertheless,...…
View Post 3 min This content is machine translated From symptom to diagnosis Gynecomastia and Adipomastia The term ” gynecomastia ” refers to the enlargement of the mammary gland in men, which may be unilateral or bilateral. True gynecomastia, caused by an increase in glandular tissue,...…
View Post 7 min This content is machine translated Plastic surgery and reconstructive microsurgery for DFS Functional limb preservation between infection control, vascular medicine and resurfacing Diabetic foot syndrome (DFS) is one of the most serious and functionally significant complications of diabetes, with a high number of functionally relevant amputations. DFS is not to be understood...… CME-Test
View Post 12 min This content is machine translated SURPASS-CVOT Tirzepatide versus Dulaglutide in T2D with ASCVD GLP-1 receptor agonists have established themselves in recent years as a class of drugs with cardiovascular protective effects in type 2 diabetes. For dulaglutide, the 2019 REWIND study showed that...…
View Post 13 min This content is machine translated What the latest studies on the entire EF spectrum mean for clinical practice Heart Failure – The 2026 Evidence Update Since the release of the 2021 ESC guidelines and the 2022 AHA/ACC/HFSA guidelines, research on heart failure has reached a remarkable level of intensity. Nonsteroidal mineralocorticoid receptor antagonists and incretin-based...…
View Post 5 min This content is machine translated CKD in People with Type 2 Diabetes: Evidence-Based, Optimized Treatment SGLT-2 inhibitors and GLP-1 receptor agonists: significant improvement in renal outcomes Approximately 30–40% of patients with type 2 diabetes develop chronic kidney disease (CKD) over time. In “landmark” studies such as CREDENCE, DAPA-CKD, EMPA-KIDNEY, and several others, SGLT-2 (sodium-glucose-linked transporter 2)...…
